NEWS

Veteran Translational Medicine and Clinical Development Leader Joins as Company Prepares to Advance its Lead Program for Remyelination in Multiple Sclerosis to Human Studies.

Current therapies targeting multiple sclerosis (MS) primarily target the symptoms of the disease but do not repair neurological damage caused by the condition. This is something that Chris Loose, PhD, CEO and co-founder of Progentos Therapeutics, and his colleagues are hoping to remedy.

Progentos says the money will go toward expanding its pipeline and pushing an experimental treatment for multiple sclerosis through “proof of concept” testing.

Progentos is doing remarkable work, and its lead pipeline candidate has the potential to be the first restorative therapy and transform the treatment of MS

A new biotech emerged to take forward the lead preclinical work developed by Frequency Therapeutics, a regenerative medicines company that...